Structure of neurotropic adeno-associated virus AAVrh.8

Journal of Structural Biology

Volumn 192, Issue 1, 2015, Pages 21-36

  Halder, Sujata ^a   Van Vliet, Kim ^a   Smith, J Kennon ^a   Duong, Thao Thi Phuong ^a   McKenna, Robert ^a   Wilson, James M ^b   Agbandje McKenna, Mavis ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AAV vectors; Capsid structure; Gene therapy; Neurotropism; Parvovirus; X ray crystallography

Indexed keywords

CAPSID PROTEIN; HEPARIN; MONOCLONAL ANTIBODY; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; ADENO ASSOCIATED VIRUS RHESUS ISOLATE 8; ALPHA HELIX; ANTIGENICITY; ARTICLE; BETA SHEET; CONTROLLED STUDY; CROSS REACTION; GENETIC TRANSDUCTION; NONHUMAN; PARVOVIRIDAE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; RECEPTOR BINDING; SEQUENCE HOMOLOGY; SERUM; STRUCTURE ANALYSIS; SURFACE PROPERTY; VIRUS ATTACHMENT; VIRUS CAPSID; VIRUS MORPHOLOGY; X RAY CRYSTALLOGRAPHY; AMINO ACID SEQUENCE; BINDING SITE; CHEMISTRY; DEPENDOPARVOVIRUS; GENE VECTOR; MOLECULAR GENETICS; MOLECULAR MODEL; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; ULTRASTRUCTURE; VIRION;

AMINO ACID SEQUENCE; BINDING SITES; CAPSID PROTEINS; CRYSTALLOGRAPHY, X-RAY; DEPENDOVIRUS; GENETIC VECTORS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; VIRION;

EID: 84983132701     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2015.08.017     Document Type: Article

References (124)

1. Adachi K., Enoki T., Kawano Y., Veraz M., Nakai H. Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing. Nat. Commun. 2014, 5:3075.
2. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., McCoy A.J., Moriarty N.W., Oeffner R., Read R.J., Richardson D.C., Richardson J.S., Terwilliger T.C., Zwart P.H. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:213-221.
3. Afione S., DiMattia M.A., Halder S., Di Pasquale G., Agbandje-McKenna M., Chiorini J.A. Identification and mutagenesis of the adeno-associated virus 5 sialic acid binding region. J. Virol. 2015, 89:1660-1672.
4. Agbandje-McKenna M., Chapman M.S. Correlating structure with function in viral capsid. Parvoviruses 2006, 125-139. Hodder Arnold, London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
5. Agbandje-McKenna M., Kleinschmidt J. AAV capsid structure and cell interactions. Methods Mol. Biol. 2011, 807:47-92.
6. Agbandje-McKenna M., Llamas-Saiz A.L., Wang F., Tattersall P., Rossmann M.G. Functional implications of the structure of the murine parvovirus, minute virus of mice. Structure 1998, 6:1369-1381.
7. Akache B., Grimm D., Pandey K., Yant S.R., Xu H., Kay M.A. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J. Virol. 2006, 80:9831-9836.
8. Aslanidi G.V., Rivers A.E., Ortiz L., Song L., Ling C., Govindasamy L., Van Vliet K., Tan M., Agbandje-McKenna M., Srivastava A. Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold?. PLoS One 2013, 8:e59142.
9. Asokan A., Hamra J.B., Govindasamy L., Agbandje-McKenna M., Samulski R.J. Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J. Virol. 2006, 80:8961-8969.
10. Atchison R.W., Casto B.C., Hammon W.M. Adenovirus-associated defective virus particles. Science 1965, 149:754-756.
11. Bantel-Schaal U., zur Hausen H. Characterization of the DNA of a defective human parvovirus isolated from a genital site. Virology 1984, 134:52-63.
12. Bell C.L., Gurda B.L., Van Vliet K., Agbandje-McKenna M., Wilson J.M. Identification of the galactose binding domain of the adeno-associated virus serotype 9 capsid. J. Virol. 2012, 86:7326-7333.
13. Blacklow N.R., Hoggan M.D., Kapikian A.Z., Austin J.B., Rowe W.P. Epidemiology of adenovirus-associated virus infection in a nursery population. Am. J. Epidemiol. 1968, 88:368-378.
14. Bleker S., Sonntag F., Kleinschmidt J.A. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J. Virol. 2005, 79:2528-2540.
15. Boutin S., Monteilhet V., Veron P., Leborgne C., Benveniste O., Montus M.F., Masurier C. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 2010, 21:704-712.
16. Bowles D.E., Rabinowitz J.E., Samulski R.J. The genus dependovirus. Parvoviruses 2006, 15-23. Hodder Arnold, London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
17. Bowles D.E., McPhee S.W., Li C., Gray S.J., Samulski J.J., Camp A.S., Li J., Wang B., Monahan P.E., Rabinowitz J.E., Grieger J.C., Govindasamy L., Agbandje-McKenna M., Xiao X., Samulski R.J. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol. Ther. 2012, 20:443-455.
18. Brunger A.T. Assessment of phase accuracy by cross validation: the free R value. Methods and applications. Acta Crystallogr. D Biol. Crystallogr. 1993, 49:24-36.
19. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., Warren G.L. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 1998, 54:905-921.
20. Buller R.M., Rose J.A. Characterization of adenovirus-associated virus-induced polypeptides in KB cells. J. Virol. 1978, 25:331-338.
21. Calcedo R., Vandenberghe L.H., Gao G., Lin J., Wilson J.M. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 2009, 199:381-390.
22. Carrillo-Tripp M., Shepherd C.M., Borelli I.A., Venkataraman S., Lander G., Natarajan P., Johnson J.E., Brooks C.L., Reddy V.S. VIPERdb2: an enhanced and web API enabled relational database for structural virology. Nucleic Acids Res. 2009, 37:D436-D442.
23. Carter B.J. Adeno-associated virus vectors and biology of gene delivery. Parvoviruses 2006, 497-498. Hodder Arnold, London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
24. Chapman M.S., Agbandje-McKenna M. Atomic structure of viral particles. Parvoviruses 2006, 107-123. Hodder Arnold, London. J.R. Kerr, S.F. Cotmore, M.E. Bloom, R.M. Linden, C.R. Parrish (Eds.).
25. Chen V.B., Arendall W.B., Headd J.J., Keedy D.A., Immormino R.M., Kapral G.J., Murray L.W., Richardson J.S., Richardson D.C. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:12-21.
26. Cotmore S.F., Agbandje-McKenna M., Chiorini J.A., Mukha D.V., Pintel D.J., Qiu J., Soderlund-Venermo M., Tattersall P., Tijssen P., Gatherer D., Davison A.J. The family Parvoviridae. Arch. Virol. 2014, 159:1239-1247.
27. Coura Rdos S., Nardi N.B. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol. J. 2007, 4:99.
28. Daya S., Berns K.I. Gene therapy using adeno-associated virus vectors. Clin. Microbiol. Rev. 2008, 21:583-593.
29. DeLano W.L. The PyMOL Molecular Graphic System 2002, DeLano Scientific, San Carlos, CA.
30. DiMattia M.A., Nam H.J., Van Vliet K., Mitchell M., Bennett A., Gurda B.L., McKenna R., Olson N.H., Sinkovits R.S., Potter M., Byrne B.J., Aslanidi G., Zolotukhin S., Muzyczka N., Baker T.S., Agbandje-McKenna M. Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 2012, 86:6947-6958.
31. DiPrimio N., Asokan A., Govindasamy L., Agbandje-McKenna M., Samulski R.J. Surface loop dynamics in adeno-associated virus capsid assembly. J. Virol. 2008, 82:5178-5189.
32. Emsley P., Lohkamp B., Scott W.G., Cowtan K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:486-501.
33. Flotte T.R., Carter B.J. Adeno-associated virus vectors for gene therapy. Gene Ther. 1995, 2:357-362.
34. Foust K.D., Nurre E., Montgomery C.L., Hernandez A., Chan C.M., Kaspar B.K. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27:59-65.
35. Gao G., Vandenberghe L.H., Alvira M.R., Lu Y., Calcedo R., Zhou X., Wilson J.M. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 2004, 78:6381-6388.
36. Gao G.P., Alvira M.R., Wang L., Calcedo R., Johnston J., Wilson J.M. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11854-11859.
37. Georg-Fries B., Biederlack S., Wolf J., zur Hausen H. Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology 1984, 134:64-71.
38. Giove T.J., Sena-Esteves M., Eldred W.D. Transduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection. Exp. Eye Res. 2010, 91:652-659.
39. Girod A., Ried M., Wobus C., Lahm H., Leike K., Kleinschmidt J., Deleage G., Hallek M. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2. Nat. Med. 1999, 5:1052-1056.
40. Govindasamy L., Padron E., McKenna R., Muzyczka N., Kaludov N., Chiorini J.A., Agbandje-McKenna M. Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J. Virol. 2006, 80:11556-11570.
41. Govindasamy L., DiMattia M.A., Gurda B.L., Halder S., McKenna R., Chiorini J.A., Muzyczka N., Zolotukhin S., Agbandje-McKenna M. Structural insights into adeno-associated virus serotype 5. J. Virol. 2013, 87:11187-11199.
42. Grieger J.C., Snowdy S., Samulski R.J. Separate basic region motifs within the adeno-associated virus capsid proteins are essential for infectivity and assembly. J. Virol. 2006, 80:5199-5210.
43. Gurda B.L., Raupp C., Popa-Wagner R., Naumer M., Olson N.H., Ng R., McKenna R., Baker T.S., Kleinschmidt J.A., Agbandje-McKenna M. Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J. Virol. 2012, 86:7739-7751.
44. Gurda B.L., DiMattia M.A., Miller E.B., Bennett A., McKenna R., Weichert W.S., Nelson C.D., Chen W.J., Muzyczka N., Olson N.H., Sinkovits R.S., Chiorini J.A., Zolotutkhin S., Kozyreva O.G., Samulski R.J., Baker T.S., Parrish C.R., Agbandje-McKenna M. Capsid antibodies to different adeno-associated virus serotypes bind common regions. J. Virol. 2013, 87:9111-9124.
45. Halder S., Ng R., Agbandje-McKenna M. Parvoviruses: structure and infection. Future Virol. 2012, 7:253-278.
46. Halder S., Nam H.-J., Govindasamy L., Vogel M., Dinsart C., Salome N., McKenna R., Agbandje-McKenna M. Production, purification, crystallization and structure determination of H-1 Parvovirus. Acta Crystallogr. F 2012, 68:1571-1576.
47. Halder S., Nam H.J., Govindasamy L., Vogel M., Dinsart C., Salome N., McKenna R., Agbandje-McKenna M. Structural characterization of H-1 parvovirus: comparison of infectious virions to empty capsids. J. Virol. 2013, 87:5128-5140.
48. Handa A., Muramatsu S., Qiu J., Mizukami H., Brown K.E. Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J. Gen. Virol. 2000, 81:2077-2084.
49. Hoggan M.D., Blacklow N.R., Rowe W.P. Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc. Natl. Acad. Sci. U.S.A. 1966, 55:1467-1474.
50. Horowitz E.D., Finn M.G., Asokan A. Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection. ACS Chem. Biol. 2012, 7:1059-1066.
51. Hu C., Busuttil R.W., Lipshutz G.S. RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J. Gene Med. 2010, 12:766-778.
52. Huang L.Y., Halder S., Agbandje-McKenna M. Parvovirus glycan interactions. Curr. Opin. Virol. 2014, 7:108-118.
53. Huttner N.A., Girod A., Perabo L., Edbauer D., Kleinschmidt J.A., Buning H., Hallek M. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. Gene Ther. 2003, 10:2139-2147.
54. Johnson F.B., Ozer H.L., Hoggan M.D. Structural proteins of adenovirus-associated virus type 3. J. Virol. 1971, 8:860-863.
55. Kern A., Schmidt K., Leder C., Muller O.J., Wobus C.E., Bettinger K., Von der Lieth C.W., King J.A., Kleinschmidt J.A. Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J. Virol. 2003, 77:11072-11081.
56. Kleywegt G.J., Jones T.A. Model building and refinement practice. Methods Enzymol. 1997, 277:208-230.
57. Koerber J.T., Jang J.H., Schaffer D.V. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 2008, 16:1703-1709.
58. Kotchey N.M., Adachi K., Zahid M., Inagaki K., Charan R., Parker R.S., Nakai H. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol. Ther. 2011, 19:1079-1089.
59. Krissinel E., Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2256-2268.
60. Kronenberg S., Kleinschmidt J.A., Bottcher B. Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep. 2001, 2:997-1002.
61. Kronenberg S., Bottcher B., von der Lieth C.W., Bleker S., Kleinschmidt J.A. A conformational change in the adeno-associated virus type 2 capsid leads to the exposure of hidden VP1 N termini. J. Virol. 2005, 79:5296-5303.
62. Lerch T.F., Chapman M.S. Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B). Virology 2012, 423:6-13.
63. Lerch T.F., Xie Q., Chapman M.S. The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion. Virology 2010, 403:26-36.
64. Li W., Asokan A., Wu Z., Van Dyke T., DiPrimio N., Johnson J.S., Govindaswamy L., Agbandje-McKenna M., Leichtle S., Redmond D.E., McCown T.J., Petermann K.B., Sharpless N.E., Samulski R.J. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 2008, 16:1252-1260.
65. Lochrie M.A., Tatsuno G.P., Christie B., McDonnell J.W., Zhou S., Surosky R., Pierce G.F., Colosi P. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J. Virol. 2006, 80:821-834.
66. Maersch S., Huber A., Buning H., Hallek M., Perabo L. Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology 2010, 397:167-175.
67. Maheshri N., Koerber J.T., Kaspar B.K., Schaffer D.V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 2006, 24:198-204.
68. Matthews B.W. Solvent content of protein crystals. J. Mol. Biol. 1968, 33:491-497.
69. McCraw D.M., O'Donnell J.K., Taylor K.A., Stagg S.M., Chapman M.S. Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20. Virology 2012, 431:40-49.
70. McPherson A. Preparation and Analysis of Protein Crystals, 1st ed. 1982, Wiley, New York.
71. Melnick J.L., Mayor H.D., Smith K.O., Rapp F. Association of 20-millimicron particles with adenoviruses. J. Bacteriol. 1965, 90:271-274.
72. Michelfelder S., Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet. 2009, 67:29-60.
73. Mikals K., Nam H.J., Van Vliet K., Vandenberghe L.H., Mays L.E., McKenna R., Wilson J.M., Agbandje-McKenna M. The structure of AAVrh32.33, a novel gene delivery vector. J. Struct. Biol. 2014, 186:308-317.
74. Mingozzi F., High K.A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 2011, 12:341-355.
75. Mori S., Wang L., Takeuchi T., Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 2004, 330:375-383.
76. Moskalenko M., Chen L., van Roey M., Donahue B.A., Snyder R.O., McArthur J.G., Patel S.D. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 2000, 74:1761-1766.
77. Mueller C., Flotte T.R. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther. 2008, 15:858-863.
78. Muramatsu S., Mizukami H., Young N.S., Brown K.E. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 1996, 221:208-217.
79. Nam H.J., Gurda B.L., McKenna R., Potter M., Byrne B., Salganik M., Muzyczka N., Agbandje-McKenna M. Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking. J. Virol. 2011, 85:11791-11799.
80. Nam H.J., Lane M.D., Padron E., Gurda B., McKenna R., Kohlbrenner E., Aslanidi G., Byrne B., Muzyczka N., Zolotukhin S., Agbandje-McKenna M. Structure of adeno-associated virus serotype 8, a gene therapy vector. J. Virol. 2007, 81:12260-12271.
81. Nathwani A.C., Tuddenham E.G., Rangarajan S., Rosales C., McIntosh J., Linch D.C., Chowdary P., Riddell A., Pie A.J., Harrington C., O'Beirne J., Smith K., Pasi J., Glader B., Rustagi P., Ng C.Y., Kay M.A., Zhou J., Spence Y., Morton C.L., Allay J., Coleman J., Sleep S., Cunningham J.M., Srivastava D., Basner-Tschakarjan E., Mingozzi F., High K.A., Gray J.T., Reiss U.M., Nienhuis A.W., Davidoff A.M. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 2011, 365:2357-2365.
82. Ng R., Govindasamy L., Gurda B.L., McKenna R., Kozyreva O.G., Samulski R.J., Parent K.N., Baker T.S., Agbandje-McKenna M. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 2010, 84:12945-12957.
83. Opie S.R., Warrington K.H., Agbandje-McKenna M., Zolotukhin S., Muzyczka N. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 2003, 77:6995-7006.
84. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
85. Padron E., Bowman V., Kaludov N., Govindasamy L., Levy H., Nick P., McKenna R., Muzyczka N., Chiorini J.A., Baker T.S., Agbandje-McKenna M. Structure of adeno-associated virus type 4. J. Virol. 2005, 79:5047-5058.
86. Perabo L., Endell J., King S., Lux K., Goldnau D., Hallek M., Buning H. Combinatorial engineering of a gene therapy vector: directed evolution of adeno-associated virus. J. Gene Med. 2006, 8:155-162.
87. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera - a visualization system for exploratory research and analysis. J. Comput. Chem. 2004, 25:1605-1612.
88. Pulicherla N., Shen S., Yadav S., Debbink K., Govindasamy L., Agbandje-McKenna M., Asokan A. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther. 2011, 19:1070-1078.
89. Rabinowitz J.E., Rolling F., Li C., Conrath H., Xiao W., Xiao X., Samulski R.J. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 2002, 76:791-801.
90. Raupp C., Naumer M., Muller O.J., Gurda B.L., Agbandje-McKenna M., Kleinschmidt J.A. The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing. J. Virol. 2012, 86:9396-9408.
91. Rose J.A., Maizel J.V., Inman J.K., Shatkin A.J. Structural proteins of adenovirus-associated viruses. J. Virol. 1971, 8:766-770.
92. Rossmann M.G., Blow D.M. The detection of sub-units within the crystallographic asymmetric unit. Acta Crystallogr. 1962, 15:24-31.
93. Rossmann M.G., McKenna R., Tong L., Xia D., Dai J., Wu H., Choi H.K., Lynch R.E. Molecular replacement real-space averaging. J. Appl. Crystallogr. 1992, 25:166-180.
94. Rutledge E.A., Halbert C.L., Russell D.W. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J. Virol. 1998, 72:309-319.
95. Salganik M., Aydemir F., Nam H.J., McKenna R., Agbandje-McKenna M., Muzyczka N. Adeno-associated virus capsid proteins may play a role in transcription and second-strand synthesis of recombinant genomes. J. Virol. 2014, 88:1071-1079.
96. Salganik M., Venkatakrishnan B., Bennett A., Lins B., Yarbrough J., Muzyczka N., Agbandje-McKenna M., McKenna R. Evidence for pH-dependent protease activity in the adeno-associated virus capsid. J. Virol. 2012, 86:11877-11885.
97. Salmon F., Grosios K., Petry H. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera(R)). Expert Rev. Clin. Pharmacol. 2014, 7:53-65.
98. Schmidt M., Voutetakis A., Afione S., Zheng C., Mandikian D., Chiorini J.A. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J. Virol. 2008, 82:1399-1406.
99. Schmidt M., Govindasamy L., Afione S., Kaludov N., Agbandje-McKenna M., Chiorini J.A. Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J. Virol. 2008, 82:8911-8916.
100. Shen S., Troupes A.N., Pulicherla N., Asokan A. Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. J. Virol. 2013, 87:13206-13213.
101. Shen S., Berry G.E., Castellanos Rivera R.M., Cheung R.Y., Troupes A.N., Brown S.M., Kafri T., Asokan A. Functional analysis of the putative integrin recognition motif on adeno-associated virus 9. J. Biol. Chem. 2015, 290:1496-1504.
102. Snijder J., van de Waterbeemd M., Damoc E., Denisov E., Grinfeld D., Bennett A., Agbandje-McKenna M., Makarov A., Heck A.J. Defining the stoichiometry and cargo load of viral and bacterial nanoparticles by Orbitrap mass spectrometry. J. Am. Chem. Soc. 2014, 136:7295-7299.
103. Sonntag F., Bleker S., Leuchs B., Fischer R., Kleinschmidt J.A. Adeno-associated virus type 2 capsids with externalized VP1/VP2 trafficking domains are generated prior to passage through the cytoplasm and are maintained until uncoating occurs in the nucleus. J. Virol. 2006, 80:11040-11054.
104. Sonntag F., Kother K., Schmidt K., Weghofer M., Raupp C., Nieto K., Kuck A., Gerlach B., Bottcher B., Muller O.J., Lux K., Horer M., Kleinschmidt J.A. The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes. J. Virol. 2011, 85:12686-12697.
105. Stieger K., Cronin T., Bennett J., Rolling F. Adeno-associated virus mediated gene therapy for retinal degenerative diseases. Methods Mol. Biol. 2011, 807:179-218.
106. Summerford C., Samulski R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 1998, 72:1438-1445.
107. Summerford C., Bartlett J.S., Samulski R.J. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 1999, 5:78-82.
108. Tenney R.M., Bell C.L., Wilson J.M. AAV8 capsid variable regions at the two-fold symmetry axis contribute to high liver transduction by mediating nuclear entry and capsid uncoating. Virology 2014, 454-455:227-236.
109. Tong L., Rossmann M.G. Rotation function calculations with GLRF program. Methods Enzymol. 1997, 276:594-611.
110. Tseng Y.S., Agbandje-McKenna M. Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors. Front. Immunol. 2014, 5:9.
111. Urzhumtseva L., Afonine P., Adams P., Urzhumtsev A. Crystallographic model quality at a glance. Acta Crystallogr. D Biol. Crystallogr. 2009, 65:297-300.
112. Venkatakrishnan B., Yarbrough J., Domsic J., Bennett A., Bothner B., Kozyreva O.G., Samulski R.J., Muzyczka N., McKenna R., Agbandje-McKenna M. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J. Virol. 2013, 87:4974-4984.
113. Walters R.W., Agbandje-McKenna M., Bowman V.D., Moninger T.O., Olson N.H., Seiler M., Chiorini J.A., Baker T.S., Zabner J. Structure of adeno-associated virus serotype 5. J. Virol. 2004, 78:3361-3371.
114. Wang L., Calcedo R., Nichols T.C., Bellinger D.A., Dillow A., Verma I.M., Wilson J.M. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 2005, 105:3079-3086.
115. Wobus C.E., Hugle-Dorr B., Girod A., Petersen G., Hallek M., Kleinschmidt J.A. Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 2000, 74:9281-9293.
116. Wu P., Xiao W., Conlon T., Hughes J., Agbandje-McKenna M., Ferkol T., Flotte T., Muzyczka N. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 2000, 74:8635-8647.
117. Wu Z., Asokan A., Grieger J.C., Govindasamy L., Agbandje-McKenna M., Samulski R.J. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 2006, 80:11393-11397.
118. Xiao C., Rossmann M.G. Interpretation of electron density with stereographic roadmap projections. J. Struct. Biol. 2007, 158:182-187.
119. Xie Q., Chapman M.S. Canine parvovirus capsid structure, analyzed at 2.9 A resolution. J. Mol. Biol. 1996, 264:497-520.
120. Xie Q., Lerch T.F., Meyer N.L., Chapman M.S. Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). Virology 2011, 420:10-19.
121. Xie Q., Bu W., Bhatia S., Hare J., Somasundaram T., Azzi A., Chapman M.S. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:10405-10410.
122. Yang B., Li S., Wang H., Guo Y., Gessler D.J., Cao C., Su Q., Kramer J., Zhong L., Ahmed S.S., Zhang H., He R., Desrosiers R.C., Brown R., Xu Z., Gao G. Global CNS transduction of adult mice by intravenously delivered rAAVrh. 8 and rAAVrh.10 and nonhuman primates by rAAVrh.10. Mol. Ther. 2014, 22:1299-1309.
123. Zhang H., Yang B., Mu X., Ahmed S.S., Su Q., He R., Wang H., Mueller C., Sena-Esteves M., Brown R., Xu Z., Gao G. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 2011, 19:1440-1448.
124. Zhong L., Li B., Mah C.S., Govindasamy L., Agbandje-McKenna M., Cooper M., Herzog R.W., Zolotukhin I., Warrington K.H., Weigel-Van Aken K.A., Hobbs J.A., Zolotukhin S., Muzyczka N., Srivastava A. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7827-7832.